Abstract
Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Current Topics in Medicinal Chemistry
Title: Synergistic Approaches to Clinical Oncology Biomarker Discovery
Volume: 5 Issue: 11
Author(s): Stanley M. Belkowski, Deborah Polkovitch and Michael R. D'Andrea
Affiliation:
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Abstract: Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Export Options
About this article
Cite this article as:
Belkowski M. Stanley, Polkovitch Deborah and D'Andrea R. Michael, Synergistic Approaches to Clinical Oncology Biomarker Discovery, Current Topics in Medicinal Chemistry 2005; 5 (11) . https://dx.doi.org/10.2174/156802605774297074
DOI https://dx.doi.org/10.2174/156802605774297074 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What we have Learned from Animal Models of Mycoplasma pneumoniae Disease: Virulence Mechanisms and Host Responses
Current Pediatric Reviews Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Imaging Drug Resistance with Radiolabeled Molecules
Current Pharmaceutical Design Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Anti-Breast Cancer Agents from Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry 2(3)-Aryl-thio(oxy)-methylquinoxaline Derivatives: A New Class of P-Glycoprotein-Mediated Drug Efflux Inhibitors
Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Synthesis and Bioactivity of Novel Carvacrol and Thymol Derivatives Containing 5-Phenyl-2-furan
Letters in Drug Design & Discovery Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy
Current Topics in Medicinal Chemistry Research Progress on the Mechanisms of Combined Bevacizumab and Radiotherapy
Recent Patents on Anti-Cancer Drug Discovery Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry